Unexpectedly, the PI3K/AKT signaling pathway28 contributed to the anticancer efficacy of telmisartan against NSCLC with PPARG activation, aligning with the lung oncogenes depicted in Fig. 1. Here, PPARG is linked to non-small cell lung carcinoma.